Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10294604" target="_blank" >RIV/00216208:11130/15:10294604 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10294604

Výsledek na webu

<a href="http://dx.doi.org/10.3324/haematol.2014.109892" target="_blank" >http://dx.doi.org/10.3324/haematol.2014.109892</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2014.109892" target="_blank" >10.3324/haematol.2014.109892</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

Popis výsledku v původním jazyce

Juvenile myelomonocytic leukemia is a rare myeloproliferative disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile myelomonocytic leukemia increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenilemyelomonocytic leukemia are currently lacking. Here we propose criteria to evaluate the response to the non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogeneti

Název v anglickém jazyce

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

Popis výsledku anglicky

Juvenile myelomonocytic leukemia is a rare myeloproliferative disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile myelomonocytic leukemia increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenilemyelomonocytic leukemia are currently lacking. Here we propose criteria to evaluate the response to the non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogeneti

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

0390-6078

e-ISSN

—

Svazek periodika

100

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

6

Strana od-do

17-22

Kód UT WoS článku

000351278500018

EID výsledku v databázi Scopus

2-s2.0-84920147335